Study of Pomalidomide in Anal Cancer Precursors
This is a single centre open label phase II trial to determine the antitumor efficacy of the oral immunomodulatory agent pomalidomide in persistent human papillomavirus (HPV) -associated high grade squamous intra-epithelial lesions (HSIL) in patients with and without human immunodeficiency virus (HIV) infection.
High Grade Squamous Intra-epithelial Lesion (HSIL)
DRUG: Pomalidomide 2 MG Oral Capsule [Pomalyst]
Histological High Grade Squamous Intraepithelial Lesions (HSIL) clearance at 6 months of therapy, Histological high grade squamous intra-epithelial lesion clearance, 6 months
incidence of grade 3 and 4 adverse events and therapy delays (tolerability), incidence of grade 3 and 4 adverse events and therapy delays (tolerability), 6 months|number of subjects completing of full six month course, number of subjects completing of full six month course (feasibility of polidamide in this setting), 6 months|effect of pomalidomide on self-reported health related quality of life and cancer anxiety during and after therapy, individual patient change in quality of life questionnaire (SF12) from baseline to mid therapy and end therapy, 6 months
This is a single centre open label phase II trial to determine the antitumor efficacy of the oral immunomodulatory agent pomalidomide in persistent human papillomavirus (HPV) -associated high grade squamous intra-epithelial lesions (HSIL) in patients with and without human immunodeficiency virus (HIV) infection.